NO20025821L - 2-aminokarbonyl-9H-purinderivater - Google Patents

2-aminokarbonyl-9H-purinderivater

Info

Publication number
NO20025821L
NO20025821L NO20025821A NO20025821A NO20025821L NO 20025821 L NO20025821 L NO 20025821L NO 20025821 A NO20025821 A NO 20025821A NO 20025821 A NO20025821 A NO 20025821A NO 20025821 L NO20025821 L NO 20025821L
Authority
NO
Norway
Prior art keywords
aminocarbonyl
purine
preparation
compounds
solvates
Prior art date
Application number
NO20025821A
Other languages
English (en)
Other versions
NO20025821D0 (no
NO324426B1 (no
Inventor
Simon John Mantell
Peter Thomas Stephenson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014048A external-priority patent/GB0014048D0/en
Priority claimed from GB0024920A external-priority patent/GB0024920D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20025821D0 publication Critical patent/NO20025821D0/no
Publication of NO20025821L publication Critical patent/NO20025821L/no
Publication of NO324426B1 publication Critical patent/NO324426B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Det er beskrevet forbindelser med formel (1) og farmasøytisk akseptable: salter og solvater derav, og fremgangsmåter for fremstilling derav, mellomprodukter anvendt i fremstillingen, sammensetninger som inneholder disse og anvendelse av slike forbindelser.
NO20025821A 2000-06-06 2002-12-04 2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning NO324426B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0014048A GB0014048D0 (en) 2000-06-06 2000-06-06 Purine derivatives
GB0018246A GB0018246D0 (en) 2000-06-06 2000-07-25 Purine derivatives
GB0024920A GB0024920D0 (en) 2000-06-06 2000-10-11 Purine derivatives
PCT/IB2001/000973 WO2001094368A1 (en) 2000-06-06 2001-06-05 2-aminocarbonyl-9h-purine derivatives

Publications (3)

Publication Number Publication Date
NO20025821D0 NO20025821D0 (no) 2002-12-04
NO20025821L true NO20025821L (no) 2003-02-04
NO324426B1 NO324426B1 (no) 2007-10-08

Family

ID=27255754

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025821A NO324426B1 (no) 2000-06-06 2002-12-04 2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning

Country Status (34)

Country Link
EP (1) EP1292604B1 (no)
JP (2) JP4129176B2 (no)
KR (1) KR100484704B1 (no)
CN (1) CN1249074C (no)
AR (1) AR030289A1 (no)
AT (1) ATE431356T1 (no)
AU (2) AU6053701A (no)
BG (1) BG107216A (no)
BR (1) BR0111263A (no)
CA (1) CA2414018C (no)
CU (1) CU23240B7 (no)
CZ (1) CZ20023875A3 (no)
DE (1) DE60138702D1 (no)
DK (1) DK1292604T3 (no)
DZ (1) DZ3439A1 (no)
EA (1) EA004983B1 (no)
EE (1) EE200200678A (no)
ES (1) ES2324816T3 (no)
GC (1) GC0000287A (no)
HK (2) HK1054042A1 (no)
HR (1) HRP20020960A2 (no)
HU (1) HUP0301330A3 (no)
IL (2) IL152783A0 (no)
IS (1) IS6599A (no)
MA (1) MA26910A1 (no)
MX (1) MXPA02012033A (no)
NO (1) NO324426B1 (no)
NZ (1) NZ522184A (no)
OA (1) OA12279A (no)
PA (1) PA8518801A1 (no)
PL (1) PL360435A1 (no)
SK (1) SK16752002A3 (no)
TW (1) TWI227240B (no)
WO (1) WO2001094368A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
SG176313A1 (en) 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
GB0129270D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
AU2003234716A1 (en) * 2002-04-10 2003-10-27 Joel M. Linden Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
WO2004080411A2 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
WO2004081005A1 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
WO2005039590A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
DE602004027409D1 (de) 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7605143B2 (en) 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
CN102123990B (zh) 2008-06-19 2014-07-09 武田药品工业株式会社 杂环化合物及其用途
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
KR20120018813A (ko) 2009-05-29 2012-03-05 화이자 리미티드 글루코코티코이드 수용체 작용제
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347512C (en) * 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives

Also Published As

Publication number Publication date
KR100484704B1 (ko) 2005-04-22
WO2001094368A1 (en) 2001-12-13
CN1434830A (zh) 2003-08-06
CA2414018C (en) 2007-10-16
EP1292604A1 (en) 2003-03-19
NO20025821D0 (no) 2002-12-04
PL360435A1 (en) 2004-09-06
IL152783A0 (en) 2003-06-24
IL184144A (en) 2008-11-26
HK1089447A1 (en) 2006-12-01
BG107216A (bg) 2003-05-30
DK1292604T3 (da) 2009-06-15
HUP0301330A3 (en) 2005-02-28
MA26910A1 (fr) 2004-12-20
AU2001260537B2 (en) 2006-05-25
CU23240B7 (es) 2007-10-17
ATE431356T1 (de) 2009-05-15
IL184144A0 (en) 2007-10-31
HK1054042A1 (en) 2003-11-14
AU6053701A (en) 2001-12-17
EA200201179A1 (ru) 2003-04-24
EA004983B1 (ru) 2004-10-28
SK16752002A3 (sk) 2004-05-04
GC0000287A (en) 2006-11-01
OA12279A (en) 2003-01-01
EP1292604B1 (en) 2009-05-13
CA2414018A1 (en) 2001-12-13
PA8518801A1 (es) 2002-09-17
MXPA02012033A (es) 2003-04-25
EE200200678A (et) 2004-06-15
HRP20020960A2 (en) 2005-02-28
JP4129176B2 (ja) 2008-08-06
BR0111263A (pt) 2003-06-17
KR20030032962A (ko) 2003-04-26
CZ20023875A3 (cs) 2004-02-18
DE60138702D1 (de) 2009-06-25
ES2324816T3 (es) 2009-08-17
NZ522184A (en) 2004-05-28
NO324426B1 (no) 2007-10-08
CN1249074C (zh) 2006-04-05
TWI227240B (en) 2005-02-01
JP2003535871A (ja) 2003-12-02
DZ3439A1 (fr) 2001-12-13
IS6599A (is) 2002-10-29
JP2008150383A (ja) 2008-07-03
AR030289A1 (es) 2003-08-20
HUP0301330A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
GB0124933D0 (en) Chemical compounds
IS6658A (is) Ný efnasambönd
IS6520A (is) Ný efnasambönd
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
ATE316083T1 (de) Adamantanderivate
AU2002246728A1 (en) Carboline derivatives
NO996108L (no) 9-oksinerytromycinderivater
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
MXPA02012076A (es) Compuestos quimicos.
MXPA03009750A (es) Compuestos quimicos.
AU2002213421A1 (en) Condensed pyridoindole derivatives
AU2001266575A1 (en) Chemical compounds
MXPA03007142A (es) Derivados de carbolina.
NO20040881L (no) Orale antidiabetes midler.
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE0102055D0 (sv) New Compounds
SE0101038D0 (sv) Novel compounds
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2002213419A1 (en) Condensed pyridoindole derivatives
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
ATE274515T1 (de) Pyrazolopyridinderivate
NO20044466L (no) Plasma-karboksypeptidase B-inhibitorer
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees